Silver Book Fact

A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.

Ravina B, Fagan S, Hart R, Hovinga C, et al. Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment. Neurology. 2003; 60(8): 1234-40. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12707423

Reference

Title
Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment
Publication
Neurology
Publication Date
2003
Authors
Ravina B, Fagan S, Hart R, Hovinga C, et al
Volume & Issue
Volume 60, Issue 8
Pages
1234-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • The present value QUALY gains associated with a new drug that by 2010 could delay disease onset by 1, 3, and 5 years. The dollar value estimates range from approximately…  
  • An Alzheimer’s disease research study showed that billions of dollars could be saved if physicians could intervene before someone becomes symptomatic. This positive net savings occurred with both drug treatment…  
  • Deep brain stimulation, an electrical signal delivered deep inside the brain, provides significant symptomatic relief for Parkinson’s patients whose medication is no longer effective.  
  • Slowing the Progress of Parkinson’s Disease Would Save Money
     
  • Americans Age 65 and Older with Alzheimer’s Disease, 2010–2050